Drug Profile


Alternative Names: PRXASL

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PhaseRx
  • Class
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inborn urea cycle disorders

Most Recent Events

  • 28 Nov 2017 The European Medicines Agency's Committee for Orphan Medicinal Products recommends orphan drug designation for PRX-ASL in European Union for Inborn urea cycle disorders (argininosuccinate lyase deficiency)
  • 20 Sep 2017 PRX ASL receives Orphan Drug status for Inborn urea cycle disorders in USA
  • 08 Nov 2016 Preclinical pharmacodynamics and adverse events data released by PhaseRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top